心力衰竭中的阿尔多和:克服临床实践中的这一主要障碍
Laibah Arshad Khan1, Adeena Jamil2, Stephen J Greene3,4
1Department of Medicine, University of Mississippi Medical Center Jackson, MS, US.
Cardiac failure review
|January 28, 2025
概括
不正常的血清 (失血症) 在心力衰竭 (HF) 中很常见,并与不良结果有关. 控制水平对于优化HF治疗和改善患者存活率至关重要.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 阿尔多斯特调节液体和电解质平衡,对心血管健康至关重要.
- 失调的阿尔多在心力衰竭 (HF) 中驱动心脏重塑和糟糕的结果.
- 平衡对于心脏,胃肠道和神经肌肉功能至关重要,受到阿尔多的影响.
研究的目的:
- 审查心力衰竭中失血 (低血和高血) 的影响.
- 讨论当前和未来的高频硬质血症管理策略.
- 突出结合剂在优化HF治疗中的作用.
主要方法:
- 对阿尔多素,和心力衰竭研究的文献综述.
- 对HF患者血清水平的预后影响的分析.
- 讨论治疗干预措施,包括阿尔多斯特调节剂和结合剂.
主要成果:
- 失血症在HF中普遍存在,原因是疾病,疗法和诸如CKD之类的并发症.
- 低血和高血都与高风的死亡率增加和不良事件有关.
- 高血症限制了基本RAAS抑制剂的使用,影响了长期生存.
结论:
- 有效地管理失血症对于优化HF治疗至关重要.
- 新型结合剂为管理高血症提供了有希望的方法,使RAAS抑制剂定位更好.
- 未来的阿尔多激素调节疗法有可能改善HF管理.
相关概念视频
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Antihypertensive Drugs: Potassium-Sparing Diuretics
442
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
442
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Heart Failure Drugs: Inotropic Agents
507
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
507
Regulation of Sodium and Potassium
384
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
384
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311


